134 related articles for article (PubMed ID: 24942859)
1. Loss of periplakin expression is associated with pathological stage and cancer-specific survival in patients with urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Sato Y; Kuruma H; Kamata Y; Nishimori T; Tomonaga T; Nomura F; Egawa S; Iwamura M
Biomed Res; 2014; 35(3):201-6. PubMed ID: 24942859
[TBL] [Abstract][Full Text] [Related]
2. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.
Naruse K; Yamada Y; Nakamura K; Aoki S; Taki T; Zennami K; Katsuda R; Watanabe M; Nishikawa G; Itoh Y; Mitsui K; Hibi H; Honda N
Oncol Rep; 2010 Jun; 23(6):1577-83. PubMed ID: 20428812
[TBL] [Abstract][Full Text] [Related]
3. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
4. Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Matsumoto T; Nagashio R; Nishimori T; Tomonaga T; Nomura F; Sato Y; Kitasato H; Iwamura M
Asian Pac J Cancer Prev; 2014; 15(22):9927-31. PubMed ID: 25520130
[TBL] [Abstract][Full Text] [Related]
5. Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study.
Osawa T; Abe T; Shinohara N; Harabayashi T; Sazawa A; Kubota K; Matsuno Y; Shibata T; Shinno Y; Kamota S; Minami K; Sakashita S; Kumagai A; Mori T; Nonomura K
Int J Urol; 2009 Mar; 16(3):274-8; discussion 278. PubMed ID: 19087211
[TBL] [Abstract][Full Text] [Related]
6. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis.
Canter D; Guzzo T; Resnick M; Magerfleisch L; Sonnad S; Bergey M; Tomazewski J; Vaughn D; Van Arsdalen K; Malkowicz B
BJU Int; 2008 Sep; 102(8):952-7. PubMed ID: 18485042
[TBL] [Abstract][Full Text] [Related]
7. TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy.
Nomura M; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Nishi M; Ryo A; Nagashio R; Sato Y; Iwamura M
Cancer Biomark; 2019; 24(1):91-96. PubMed ID: 30475756
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
11. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
12. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
13. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.
Matsumoto K; Irie A; Satoh T; Ishii J; Iwabuchi K; Iwamura M; Egawa S; Baba S
Urology; 2007 Sep; 70(3):602-7. PubMed ID: 17688917
[TBL] [Abstract][Full Text] [Related]
14. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy.
Masson-Lecomte A; Vordos D; Hoznek A; Yiou R; Allory Y; Abbou CC; de la Taille A; Salomon L
Ann Surg Oncol; 2013 Apr; 20(4):1389-94. PubMed ID: 23208127
[TBL] [Abstract][Full Text] [Related]
15. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
16. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics.
Tabriz HM; Olfati G; Ahmadi SA; Yusefnia S
Asian Pac J Cancer Prev; 2013; 14(8):4539-43. PubMed ID: 24083698
[TBL] [Abstract][Full Text] [Related]
19. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
20. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
